Amit Amin, MD
Interventional Cardiology · Lafayette, LANPI 1144458027
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 37.1% of the total. Reporting peaked in 2023 at $22,494 and has fallen 64.3% since, to $8,021 in 2025. Among interventional cardiology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 675 payments — averaging $121.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$30K
- Terumo Medical Corporation$12K
- Penumbra, Inc.$10K
- Boston Scientific$7K
- Philips North America LLC$6K
- Abiomed$5K
- plus $12K from 52 others
What the payments were for
- Consulting fees$30,37837%
- Speaking & faculty fees$12,03515%
- Travel & lodging$11,87215%
- Food & beverage$27,53334%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$8,274
- Navicross$7,576
- GlideWire$6,537
- R2P MISAGO$6,519
- METACROSS OTW$6,400
- TR Band$6,400
- Spectranetics Undiv$3,249
- GENERAL - THERAPIES$2,292
- Impella$2,084
- Azur CX Detachable$1,998
- Venclose Maven Catheter$1,701
- STINGRAY$941
- AZUR$836
- Penumbra System$787
- Optitorque$776
- Heartrail$776
- GENERAL VASCULAR ACCESS$748
- GENERAL VASCULAR INTERVENTION$518
- LUTONIX$511
- RotarexS 6 F x 135 cm$502
How this compares
$81,818 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 424 | $361,283 |
| EntrestoSacubitril/Valsartan | 274 | $272,650 |
| XareltoRivaroxaban | 246 | $214,820 |
| Repatha SureclickEvolocumab | 117 | $98,557 |
| FarxigaDapagliflozin Propanediol | 90 | $68,008 |
| BrilintaTicagrelor | 48 | $46,355 |
| Praluent PenAlirocumab | 38 | $34,318 |
| JardianceEmpagliflozin | 24 | $17,115 |
| Metoprolol Succinate | 601 | $8,085 |
| Rosuvastatin Calcium | 582 | $6,112 |
| Atorvastatin Calcium | 645 | $5,986 |
| ClopidogrelClopidogrel Bisulfate | 688 | $5,983 |
| VascepaIcosapent Ethyl | 12 | $5,112 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 24 | $4,904 |
| Ranolazine ErRanolazine | 58 | $3,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $361,283424 claims |
| NovartisEntresto | $381 | $272,650274 claims |
| Johnson & JohnsonXarelto | $386 | $214,820246 claims |
| AstraZenecaFarxiga, Brilinta | $116 | $114,362138 claims |
| Boehringer IngelheimJardiance | $40 | $17,11524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Lafayette
- Ankur LodhaLafayette$640K
- Agostino IngraldiLafayette$315K
- Louis SalvaggioLafayette$214K
- Eric ThomasseeLafayette$149K
- Raghotham PatlolaLafayette$76K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Rajan PatelNew Orleans$517K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.